Soligenix Inc. (NASDAQ: SNGX) completed a Phase 2a clinical trial of SGX945 for Behçet's Disease, achieving biological efficacy in treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE